RxDoctor Payments Data

Geetha Palaniappan, MD

Internal Medicine · Papillion, NENPI 1376638668

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $251 of the $285 with a category attached, or 88.2%. 11 manufacturers reported payments, led by AbbVie at 37.1% of the total.

$285in general payments, 2019–2025

Across 17 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$106
  • Pfizer$32
  • Astrazeneca UK Limited$30
  • Johnson & Johnson$21
  • Sobi, Inc$17
  • Genentech, Inc.$16
  • plus $64 from 5 others
$93,630in research payments, 2019–2025

Across 10 payments — averaging $9363.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Jazz Pharmaceuticals Inc.$56K
  • E.r. Squibb & Sons, L.L.C.$27K
  • Pfizer$10K

What the payments were for

  • Food & beverage$25188%
  • Education$3412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$285 in reported general payments places this provider in the 65th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$2,697,060
Medicare patients
665
Services billed
134,102

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide11$272,043
JakafiRuxolitinib Phosphate12$210,033
KisqaliRibociclib Succinate12$204,245
CalquenceAcalabrutinib Maleate14$190,282
ImbruvicaIbrutinib13$187,559
EliquisApixaban30$23,713
Exemestane99$13,370
Letrozole348$6,829
Anastrozole299$4,603
Enoxaparin Sodium11$2,318
Tamoxifen Citrate37$1,085
Hydroxyurea29$704
Gabapentin60$674
Dexamethasone25$536
Lidocaine-PrilocaineLidocaine/Prilocaine34$401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$23,71330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Papillion

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →